Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : APG-1387
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APG-1387 is novel and highly specific small molecule IAP antagonist designed to restore caspase activity and induce apoptosis, as component of combination therapy with immuno-oncology or chemotherapy treatment for solid tumors.
Product Name : APG-1387
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : APG-1387
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : APG-1387,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Findings from the preclinical study show that APG-1387 is able to clear chronic HBV infection in various mouse models with a unique induction of apoptosis and immunoregulation mechanism.
Product Name : APG-1387
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 27, 2020
Lead Product(s) : APG-1387,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : APG-1387,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The global multi-center, open-label Phase II study is designed to evaluate the safety and efficacy of APG-1387 in combination with entecavir in patients with CHB who are treatment-naive or -experienced.
Product Name : APG-1387
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2020
Lead Product(s) : APG-1387,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : APG-1387,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The multi-center, open-label clinical trial is comprised of a Phase Ib dose-escalation study and a Phase II efficacy study.
Product Name : APG-1387
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2020
Lead Product(s) : APG-1387,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable